These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31788129)

  • 1. SPINK1 is a prognosis predicting factor of non-small cell lung cancer and regulates redox homeostasis.
    Guo M; Zhou X; Han X; Zhang Y; Jiang L
    Oncol Lett; 2019 Dec; 18(6):6899-6908. PubMed ID: 31788129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer.
    Li D; Zhang X; Ding Z; Ai R; Shi L; Wang Z; He Q; Dong Y; Zhu Y; Ouyang W; He Y
    Cell Biochem Biophys; 2022 Dec; 80(4):807-818. PubMed ID: 36194314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.
    Chen YT; Tseng TT; Tsai HP; Kuo SH; Huang MY; Wang JY; Chai CY
    Hum Cell; 2022 Nov; 35(6):1912-1927. PubMed ID: 36053457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.
    Chen YT; Tsao SC; Yuan SS; Tsai HP; Chai CY
    Pathol Oncol Res; 2015 Sep; 21(4):1201-8. PubMed ID: 26037168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy.
    Chen YT; Tsao SC; Tsai HP; Wang JY; Chai CY
    J Clin Pathol; 2016 Apr; ():. PubMed ID: 27107100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker.
    Xu L; Lu C; Huang Y; Zhou J; Wang X; Liu C; Chen J; Le H
    BMB Rep; 2018 Dec; 51(12):648-653. PubMed ID: 30545439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma.
    Räsänen K; Lehtinen E; Nokelainen K; Kuopio T; Hautala L; Itkonen O; Stenman UH; Koistinen H
    Mol Carcinog; 2016 Dec; 55(12):2010-2023. PubMed ID: 26663388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.
    Mehner C; Oberg AL; Kalli KR; Nassar A; Hockla A; Pendlebury D; Cichon MA; Goergen KM; Maurer MJ; Goode EL; Keeney GL; Jatoi A; Sahin-Tóth M; Copland JA; Radisky DC; Radisky ES
    Oncotarget; 2015 Nov; 6(34):35737-54. PubMed ID: 26437224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.
    Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K
    Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases.
    Ohmuraya M; Yamamura K
    Exp Anim; 2011; 60(5):433-44. PubMed ID: 22041280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization.
    Suwa T; Kobayashi M; Shirai Y; Nam JM; Tabuchi Y; Takeda N; Akamatsu S; Ogawa O; Mizowaki T; Hammond EM; Harada H
    JCI Insight; 2021 Nov; 6(21):. PubMed ID: 34747365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serine peptidase inhibitor Kazal type I (SPINK1) promotes BRL-3A cell proliferation via p38, ERK, and JNK pathways.
    Chang C; Zhao W; Luo Y; Xi L; Chen S; Zhao C; Wang G; Guo J; Xu C
    Cell Biochem Funct; 2017 Aug; 35(6):339-348. PubMed ID: 28845526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Roles of SPINK1 in Cancer.
    Räsänen K; Itkonen O; Koistinen H; Stenman UH
    Clin Chem; 2016 Mar; 62(3):449-57. PubMed ID: 26656134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
    Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
    J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Roles of SPINK1 in Cancers.
    Lin TC
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD7 is a prognosis predicting factor of breast cancer and regulates redox homeostasis.
    Huang R; Li X; Yu Y; Ma L; Liu S; Zong X; Zheng Q
    Oncotarget; 2017 Nov; 8(55):94080-94090. PubMed ID: 29212211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer.
    Soon WW; Miller LD; Black MA; Dalmasso C; Chan XB; Pang B; Ong CW; Salto-Tellez M; Desai KV; Liu ET
    EMBO Mol Med; 2011 Aug; 3(8):451-64. PubMed ID: 21656687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer.
    Ida S; Ozaki N; Araki K; Hirashima K; Zaitsu Y; Taki K; Sakamoto Y; Miyamoto Y; Oki E; Morita M; Watanabe M; Maehara Y; Yamamura K; Baba H; Ohmuraya M
    Mol Cancer Res; 2015 Jul; 13(7):1130-8. PubMed ID: 25804623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.